Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting Cellular Senescence Enhances Post-Burn Wound Healing in Aged Mice.

Shock (Augusta, Ga.)·2026

Same author

Therapeutic implications of epigenetic alterations in burns: a new frontier in burn medicine.

Clinical science (London, England : 1979)·2026

Same author

Interpreting metformin safety: the importance of context, selection, and monitoring.

Critical care (London, England)·2026

Same author

Endocrine disruptions in thermal injuries: exploring immune system interactions.

Physiological reviews·2026

Same author

The role of artificial intelligence in burn assessment, complication diagnosis, and outcome prediction: a narrative review.

Burns & trauma·2026

Same author

Mitochondrial control of fuel switching via carnitine biosynthesis.

Science (New York, N.Y.)·2026

Search research articles

Related Experiment Video

Updated: Nov 8, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Interleukin-6 blockade, a potential adjunct therapy for post-burn hypermetabolism.

Dalia Barayan¹, Abdikarim Abdullahi¹, Roohi Vinaik¹

¹Sunnybrook Research Institute, Toronto, ON, Canada.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology

|April 19, 2021

Summary

Blocking interleukin-6 (IL-6) in burn patients reduces weight loss and improves organ function. This targeted therapy shows promise for treating severe burn complications and enhancing patient recovery.

Keywords:

anti-IL-6 mAb burn effectiveness hypermetabolism interleukin-6 safety

More Related Videos

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Rat Burn Model to Study Full-Thickness Cutaneous Thermal Burn and Infection

Rat Burn Model to Study Full-Thickness Cutaneous Thermal Burn and Infection

Published on: August 23, 2022

Related Experiment Videos

Last Updated: Nov 8, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Rat Burn Model to Study Full-Thickness Cutaneous Thermal Burn and Infection

Rat Burn Model to Study Full-Thickness Cutaneous Thermal Burn and Infection

Published on: August 23, 2022

Area of Science:

Immunometabolism
Trauma response
Wound healing

Background:

Severe burns trigger a hypermetabolic stress response, leading to significant morbidity and mortality.
Interleukin-6 (IL-6) is identified as a key mediator of post-burn hypermetabolism and associated complications.
Current treatments struggle to fully restore metabolic function after severe burns.

Purpose of the Study:

To investigate the safety and efficacy of blocking IL-6 in a murine model of severe burns.
To evaluate the impact of anti-IL-6 monoclonal antibody (mAb) treatment on post-burn hypermetabolism and organ dysfunction.

Main Methods:

Utilized a validated anti-IL-6 monoclonal antibody (mAb) in an experimental murine model.
Administered daily anti-IL-6 mAb post-burn to assess its effects on weight, mortality, adipose tissue, liver function, and skin pathology.

Main Results:

Daily anti-IL-6 mAb administration prevented burn-induced weight loss without increasing mortality.
IL-6 blockade suppressed adipose tissue thermogenic activation and wasting, reduced lipolysis, and decreased hepatic lipotoxicity and dysfunction.
Treatment with anti-IL-6 mAb reduced collagen deposition and suppressed genes associated with fibrosis and scarring in the skin.

Conclusions:

Post-burn IL-6 blockade significantly improves systemic hypermetabolism by mitigating pathological changes in immunometabolic organs.
Anti-IL-6 interventions demonstrate therapeutic potential for improving outcomes, quality of life, and survival in burn patients.
Targeting IL-6 offers a promising strategy to restore metabolic homeostasis and reduce long-term complications after severe burns.